Literature DB >> 2110016

Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice.

A K Myers1, J W Robey, R M Price.   

Abstract

1. The toxicity of intravenous recombinant human tumour necrosis factor (rhTNF), a TNF fragment (TNF114-130), endotoxin and combinations of rhTNF or TNF114-130 were tested in mice. Neither rhTNF nor TNF114-130 was lethal alone, but when combined with a non-lethal dose of endotoxin, rhTNF provoked dose-dependent mortality, as did higher doses of endotoxin alone. 2. Both the toxicity and the vasopermeability changes induced by endotoxin alone were blocked by the platelet-activating factor (PAF) antagonist BN52021, indomethacin or the dual cyclo-oxygenase/lipoxygenase inhibitor BW755C. 3. The lethality of the combined low dose endotoxin/rhTNF challenge was unaffected by pretreatment with BN52021, indomethacin or BW755C, or by treatment at 6 h intervals with BN52021 or BW755C. 4. The results of these studies suggest that TNF, a putative, early mediator of septic or endotoxin shock, cannot by itself mimic all of the effects of bacterial endotoxin in the model used in this study. Apparently, TNF works synergistically with other mediators whose release is stimulated by endotoxin. 5. The results also suggest that the mechanism of shock production by the rhTNF/endotoxin combination in mice is not dependent on the early stimulation of eicosanoid or PAF synthesis by rhTNF.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110016      PMCID: PMC1917357          DOI: 10.1111/j.1476-5381.1990.tb12957.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  A new approach to anti-inflammatory drugs.

Authors:  G A Higgs; R J Flower; J R Vane
Journal:  Biochem Pharmacol       Date:  1979-06-15       Impact factor: 5.858

2.  Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor.

Authors:  X M Sun; W Hsueh
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

3.  Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.

Authors:  D A Handley; R G Van Valen; M K Melden; W J Houlihan; R N Saunders
Journal:  J Pharmacol Exp Ther       Date:  1988-11       Impact factor: 4.030

4.  Protective effects of trans-13-APT, a thromboxane receptor antagonist, in endotoxemia.

Authors:  L S Olanoff; J A Cook; T Eller; D R Knapp; P V Halushka
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jan-Feb       Impact factor: 3.105

5.  Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor.

Authors:  N Satomi; A Sakurai; R Haranaka; K Haranaka
Journal:  J Biol Response Mod       Date:  1988-02

6.  Thromboxane agonism and antagonism in a mouse sudden death model.

Authors:  A Myers; J Penhos; E Ramey; P Ramwell
Journal:  J Pharmacol Exp Ther       Date:  1983-02       Impact factor: 4.030

7.  Response of mice and mouse platelets to acetyl glyceryl ether phosphorylcholine.

Authors:  E Lanara; C Vakirtzi-Lemonias; L Kritikou; C A Demopoulos
Journal:  Biochem Biophys Res Commun       Date:  1982-12-31       Impact factor: 3.575

8.  Glucocorticoid protection against PAF-acether toxicity in mice.

Authors:  A Myers; E Ramey; P Ramwell
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

9.  Induction of tumor necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A.

Authors:  P A Kiener; F Marek; G Rodgers; P F Lin; G Warr; J Desiderio
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

10.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.

Authors:  A Waage; P Brandtzaeg; A Halstensen; P Kierulf; T Espevik
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  12 in total

1.  Divergent mechanisms of action of the inflammatory cytokines interleukin 1-beta and tumour necrosis factor-alpha in mouse cremasteric venules.

Authors:  R E Young; R D Thompson; S Nourshargh
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 3.  Role of platelet-activating factor in cell death signaling in the cornea: A review.

Authors:  Salomon Esquenazi; Haydee E P Bazan
Journal:  Mol Neurobiol       Date:  2010-04-30       Impact factor: 5.590

4.  Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice.

Authors:  M Ogata; T Matsumoto; M Kamochi; S I Yoshida; Y Mizuguchi; A Shigematsu
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 5.  Immunotherapy in the management of sepsis.

Authors:  E A Fagan; M Singer
Journal:  Postgrad Med J       Date:  1995-02       Impact factor: 2.401

6.  Bile mediates intestinal pathology in endotoxemia in rats.

Authors:  G D Jackson; Y Dai; W A Sewell
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

7.  Inhibition of endotoxin-induced hypothermia and serum TNF-alpha levels in CD-1 mice by various pharmacological agents.

Authors:  S J Ochalski; D A Hartman; M T Belfast; T L Walter; K B Glaser; R P Carlson
Journal:  Agents Actions       Date:  1993

8.  Anti-inflammatory and analgesic effects of magnolol.

Authors:  J P Wang; M F Hsu; S L Raung; C C Chen; J S Kuo; C M Teng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-12       Impact factor: 3.000

Review 9.  Strategies to improve drug development for sepsis.

Authors:  Mitchell P Fink; H Shaw Warren
Journal:  Nat Rev Drug Discov       Date:  2014-09-05       Impact factor: 84.694

10.  Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo.

Authors:  K Takada; N Ohno; T Yadomae
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.